Table 2.
Antifungal susceptibility results for 49 Candida parapsilosis isolates tested with the Sensititre YeastOne® method.
| Antifungal agent | No. of isolatesa with MIC (μg/mL) of: | Categories according to clinical breakpointsb | Categories according to epidemiological cutoffsb | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.008 | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64 | Susceptible | Susceptible dose-dependent or intermediate | Resistant | Wild-type | Non-wild-type | |
| AMB | 22 | 24 | 3 | – | – | – | 49 (100) | ||||||||||||
| FLZ | 1 | 4 | 44 | – | – | 49 (100) | 49 (100) | ||||||||||||
| ITZ | 11 | 17 | 18 | 3 | – | – | – | 49 (100) | |||||||||||
| PSZ | 12 | 15 | 16 | 6 | – | – | – | 49 (100) | |||||||||||
| VRZ | 1 | 8 | 14 | 21 | 5 | 1 (2.0) | 22 (44.9) | 26 (53.1) | 49 (100) | ||||||||||
| ANF | 2 | 26 | 21 | 49 (100) | – | – | 49 (100) | ||||||||||||
| CSF | 17 | 27 | 5 | 49 (100) | – | – | 49 (100) | ||||||||||||
| MCF | 10 | 38 | 1 | 49 (100) | – | – | 49 (100) | ||||||||||||
| FLC | 42 | 6 | 1 | – | – | – | 49 (100) | ||||||||||||
AMB, amphotericin B; FLZ, fluconazole; ITZ, itraconazole; PSZ, posaconazole; VRZ, voriconazole; ANF, anidulafungin; CSF, caspofungin; MCF, micafungin; FLC, flucytosine. Bold and underline indicates MIC50 and MIC90 values, respectively.
Excludes isolates not saved for later use (n = 2) or not providing growth when recovered from their frozen stocks (n = 3). MIC results were interpreted according to clinical breakpoints (all antifungals excluding AMB, ITZ, PSZ, and FLC) and to epidemiological cutoffs (all antifungals). When the isolates were retested with the Clinical and Laboratory Standards Institute reference method for only FLZ and VRZ, MIC results confirmed 49 isolates as FLZ resistant and 48 isolates as VRZ resistant. One isolate remained classified as VRZ susceptible dose-dependent.
Results shown as n (%).